Alzheimer - Wiki-Pi

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide
STK11 and TP53	serine/threonine kinase 11	tumor protein p53	Insulin receptor signalling cascade Integration of energy metabolism IRS-mediated signalling Regulation of AMPK activity via LKB1 mTOR signalling IRS-related events mTOR signalling IGF1R signaling cascade IRS-related events triggered by IGF1R IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Energy dependent regulation of mTOR by LKB1-AMPK AMPK inhibits chREBP transcriptional activation activity PKB-mediated events PI3K Cascade PKB-mediated events PI3K Cascade Signaling by Insulin receptor	Cellular Senescence Activation of BH3-only proteins p53-Dependent G1/S DNA damage checkpoint Oncogene Induced Senescence p53-Dependent G1 DNA Damage Response Formation of Senescence-Associated Heterochromatin Foci (SAHF) Pre-NOTCH Transcription and Translation Stabilization of p53 Transcriptional activation of p53 responsive genes Programmed Cell Death Pre-NOTCH Expression and Processing G1/S DNA Damage Checkpoints Intrinsic Pathway for Apoptosis Transcriptional activation of cell cycle inhibitor p21 DNA Damage/Telomere Stress Induced Senescence Signaling by NOTCH Factors involved in megakaryocyte development and platelet production Activation of NOXA and translocation to mitochondria Oxidative Stress Induced Senescence Autodegradation of the E3 ubiquitin ligase COP1 Activation of PUMA and translocation to mitochondria Cell Cycle Checkpoints
TP53 and HECW1	tumor protein p53	HECT, C2 and WW domain containing E3 ubiquitin protein ligase 1	Cellular Senescence Activation of BH3-only proteins p53-Dependent G1/S DNA damage checkpoint Oncogene Induced Senescence p53-Dependent G1 DNA Damage Response Formation of Senescence-Associated Heterochromatin Foci (SAHF) Pre-NOTCH Transcription and Translation Stabilization of p53 Transcriptional activation of p53 responsive genes Programmed Cell Death Pre-NOTCH Expression and Processing G1/S DNA Damage Checkpoints Intrinsic Pathway for Apoptosis Transcriptional activation of cell cycle inhibitor p21 DNA Damage/Telomere Stress Induced Senescence Signaling by NOTCH Factors involved in megakaryocyte development and platelet production Activation of NOXA and translocation to mitochondria Oxidative Stress Induced Senescence Autodegradation of the E3 ubiquitin ligase COP1 Activation of PUMA and translocation to mitochondria Cell Cycle Checkpoints	misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling TCF dependent signaling in response to WNT RNF mutants show enhanced WNT signaling and proliferation XAV939 inhibits tankyrase, stabilizing AXIN degradation of DVL Signaling by Wnt Signaling by WNT in cancer
APP and KRAS	amyloid beta (A4) precursor protein	Kirsten rat sarcoma viral oncogene homolog	Signaling by GPCR Platelet degranulation Metabolic disorders of biological oxidation enzymes RIP-mediated NFkB activation via ZBP1 Formyl peptide receptors bind formyl peptides and many other ligands Amyloids Toll Like Receptor TLR1:TLR2 Cascade Peptide ligand-binding receptors Toll Like Receptor 5 (TLR5) Cascade The NLRP3 inflammasome Gastrin-CREB signalling pathway via PKC and MAPK Response to elevated platelet cytosolic Ca2+ MyD88 dependent cascade initiated on endosome Toll Like Receptor 9 (TLR9) Cascade G alpha (i) signalling events TRIF-mediated TLR3/TLR4 signaling Toll Like Receptor 2 (TLR2) Cascade G alpha (q) signalling events GPCR downstream signaling Toll Like Receptor 4 (TLR4) Cascade Toll Like Receptor 3 (TLR3) Cascade Platelet activation, signaling and aggregation TAK1 activates NFkB by phosphorylation and activation of IKKs complex Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD) G alpha (q) signalling events Class A/1 (Rhodopsin-like receptors) Toll Like Receptor 7/8 (TLR7/8) Cascade Toll Like Receptor TLR6:TLR2 Cascade DEx/H-box helicases activate type I IFN and inflammatory cytokines production Activated TLR4 signalling MyD88 cascade initiated on plasma membrane ZBP1(DAI) mediated induction of type I IFNs ECM proteoglycans MyD88:Mal cascade initiated on plasma membrane TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation Advanced glycosylation endproduct receptor signaling Innate Immune System Inflammasomes Cytosolic sensors of pathogen-associated DNA MyD88-independent cascade GPCR ligand binding Toll-Like Receptors Cascades RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways Toll Like Receptor 10 (TLR10) Cascade Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways TRAF6 mediated NF-kB activation	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease SHC-mediated cascade MEK activation FCERI mediated MAPK activation Signaling by EGFRvIII in Cancer SHC1 events in ERBB2 signaling Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Gastrin-CREB signalling pathway via PKC and MAPK p38MAPK events SOS-mediated signalling SHC-mediated signalling Signaling by PDGF DAP12 interactions SHC-related events triggered by IGF1R GRB2 events in EGFR signaling Signaling by ERBB4 Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins SHC1 events in ERBB4 signaling Signaling by VEGF Downstream signal transduction Signalling to RAS Signaling by FGFR mutants Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Interleukin-2 signaling Frs2-mediated activation Signaling by Leptin Adaptive Immune System Signalling to ERKs Prolonged ERK activation events Axon guidance IRS-mediated signalling IGF1R signaling cascade VEGFA-VEGFR2 Pathway IRS-related events triggered by IGF1R EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling VEGFR2 mediated cell proliferation RAF phosphorylates MEK Downstream signaling of activated FGFR NCAM signaling for neurite out-growth RAF/MAP kinase cascade Signalling to p38 via RIT and RIN Signaling by Insulin receptor Innate Immune System Signalling by NGF Insulin receptor signalling cascade SOS-mediated signalling SHC-mediated signalling Cytokine Signaling in Immune system IRS-related events Signaling by Ligand-Responsive EGFR Variants in Cancer SHC-related events NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR ARMS-mediated activation RAF activation SHC1 events in EGFR signaling IRS-mediated signalling Activation of RAS in B cells FRS2-mediated cascade Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Constitutive Signaling by EGFRvIII
BIN1 and MYC	bridging integrator 1	v-myc avian myelocytomatosis viral oncogene homolog		Loss of Function of TGFBR2 in Cancer Signaling by NOTCH1 HD Domain Mutants in Cancer Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer SMAD2/3 MH2 Domain Mutants in Cancer Signaling by Wnt Cyclin E associated events during G1/S transition binding of TCF/LEF:CTNNB1 to target gene promoters TGFBR1 LBD Mutants in Cancer SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Generic Transcription Pathway RNF mutants show enhanced WNT signaling and proliferation G1/S Transition Signaling by NOTCH1 XAV939 inhibits tankyrase, stabilizing AXIN Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants Mitotic G1-G1/S phases FBXW7 Mutants and NOTCH1 in Cancer TGFBR2 MSI Frameshift Mutants in Cancer SMAD2/3 Phosphorylation Motif Mutants in Cancer misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Loss of Function of SMAD2/3 in Cancer Signaling by NOTCH formation of the beta-catenin:TCF transactivating complex TGFBR2 Kinase Domain Mutants in Cancer Loss of Function of SMAD4 in Cancer TGFBR1 KD Mutants in Cancer S Phase Cell Cycle, Mitotic Loss of Function of TGFBR1 in Cancer NOTCH1 Intracellular Domain Regulates Transcription Signaling by TGF-beta Receptor Complex in Cancer Signaling by TGF-beta Receptor Complex TCF dependent signaling in response to WNT Signaling by NOTCH1 PEST Domain Mutants in Cancer Cyclin A:Cdk2-associated events at S phase entry Signaling by WNT in cancer Constitutive Signaling by NOTCH1 PEST Domain Mutants SMAD4 MH2 Domain Mutants in Cancer
ERBB2 and PIK3R1	erb-b2 receptor tyrosine kinase 2	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	Signaling by the B Cell Receptor (BCR) Signaling by FGFR in disease Axon guidance PIP3 activates AKT signaling GRB7 events in ERBB2 signaling Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling Signaling by SCF-KIT SHC1 events in ERBB2 signaling Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation PI-3K cascade GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Sema4D in semaphorin signaling Sema4D induced cell migration and growth-cone collapse Innate Immune System Signaling by PDGF Downregulation of ERBB2:ERBB3 signaling Signalling by NGF DAP12 interactions GAB1 signalosome Semaphorin interactions Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Constitutive PI3K/AKT Signaling in Cancer PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by FGFR1 mutants Interleukin-7 signaling Role of phospholipids in phagocytosis Phospholipid metabolism Fcgamma receptor (FCGR) dependent phagocytosis PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling G alpha (q) signalling events Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins TCR signaling Signaling by VEGF GP1b-IX-V activation signalling Downstream signal transduction Signaling by FGFR mutants Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Downstream TCR signaling Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade VEGFA-VEGFR2 Pathway Synthesis of PIPs at the plasma membrane IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events Antigen activates B Cell Receptor (BCR) leading to generation of second messengers PI Metabolism Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Interleukin receptor SHC signaling Signaling by FGFR1 fusion mutants Constitutive Signaling by EGFRvIII PI3K Cascade	Trastuzumab Lapatinib ado-trastuzumab emtansine Pertuzumab Afatinib	Isoproterenol (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
PTEN and STK11	phosphatase and tensin homolog	serine/threonine kinase 11	Signaling by the B Cell Receptor (BCR) Downstream TCR signaling Metabolism of lipids and lipoproteins Signaling by FGFR in disease PIP3 activates AKT signaling Signaling by EGFRvIII in Cancer Synthesis of PIPs at the plasma membrane Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) PI3K/AKT activation Synthesis of IP3 and IP4 in the cytosol PI-3K cascade PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Phospholipid metabolism PI Metabolism Innate Immune System Signaling by PDGF DAP12 interactions Signalling by NGF GAB1 signalosome Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by ERBB4 Signaling by Overexpressed Wild-Type EGFR in Cancer Negative regulation of the PI3K/AKT network Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization Inositol phosphate metabolism PI3K events in ERBB4 signaling Signaling by FGFR Signaling by ERBB2 Signaling by EGFR TCR signaling Downstream signal transduction Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer PI3K/AKT Signaling in Cancer Adaptive Immune System	Insulin receptor signalling cascade Integration of energy metabolism IRS-mediated signalling Regulation of AMPK activity via LKB1 mTOR signalling IRS-related events mTOR signalling IGF1R signaling cascade IRS-related events triggered by IGF1R IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Energy dependent regulation of mTOR by LKB1-AMPK AMPK inhibits chREBP transcriptional activation activity PKB-mediated events PI3K Cascade PKB-mediated events PI3K Cascade Signaling by Insulin receptor
PAX2 and RB1	paired box 2	retinoblastoma 1		E2F mediated regulation of DNA replication DNA Damage/Telomere Stress Induced Senescence Synthesis of DNA Mitotic Prophase Cellular Senescence G1 Phase Regulation of DNA replication Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes Orc1 removal from chromatin S Phase Cyclin E associated events during G1/S transition Cell Cycle, Mitotic M Phase Orc1 removal from chromatin Cyclin D associated events in G1 Formation of Senescence-Associated Heterochromatin Foci (SAHF) G1/S Transition Removal of licensing factors from origins Cyclin A:Cdk2-associated events at S phase entry Switching of origins to a post-replicative state Mitotic G1-G1/S phases Condensation of Prophase Chromosomes Inhibition of replication initiation of damaged DNA by RB1/E2F1
EGFR and PIK3R1	epidermal growth factor receptor	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease Signaling by EGFRvIII in Cancer PLCG1 events in ERBB2 signaling SHC1 events in ERBB2 signaling Signaling by SCF-KIT DAP12 signaling Downstream signaling events of B Cell Receptor (BCR) Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants PI3K/AKT activation PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by PDGF EGFR downregulation DAP12 interactions GAB1 signalosome GRB2 events in EGFR signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling EGFR interacts with phospholipase C-gamma Signaling by ERBB2 Signaling by EGFR Downstream signal transduction Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling PI3K/AKT Signaling in Cancer Adaptive Immune System Axon guidance PIP3 activates AKT signaling L1CAM interactions EGFR Transactivation by Gastrin GRB2 events in ERBB2 signaling PI3K events in ERBB2 signaling Downstream signaling of activated FGFR Innate Immune System Signalling by NGF Signal transduction by L1 Signaling by Ligand-Responsive EGFR Variants in Cancer NGF signalling via TRKA from the plasma membrane Signaling by Overexpressed Wild-Type EGFR in Cancer Inhibition of Signaling by Overexpressed EGFR Signaling by FGFR SHC1 events in EGFR signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by FGFR1 mutants Interleukin-7 signaling Role of phospholipids in phagocytosis Phospholipid metabolism Fcgamma receptor (FCGR) dependent phagocytosis PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling G alpha (q) signalling events Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins TCR signaling Signaling by VEGF GP1b-IX-V activation signalling Downstream signal transduction Signaling by FGFR mutants Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Downstream TCR signaling Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade VEGFA-VEGFR2 Pathway Synthesis of PIPs at the plasma membrane IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events Antigen activates B Cell Receptor (BCR) leading to generation of second messengers PI Metabolism Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Interleukin receptor SHC signaling Signaling by FGFR1 fusion mutants Constitutive Signaling by EGFRvIII PI3K Cascade	Cetuximab Trastuzumab Lidocaine Gefitinib Erlotinib Lapatinib Panitumumab Flavopiridol Vandetanib S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE Afatinib	Isoproterenol (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
PIK3R1 and RB1	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	retinoblastoma 1	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by FGFR1 mutants Interleukin-7 signaling Role of phospholipids in phagocytosis Phospholipid metabolism Fcgamma receptor (FCGR) dependent phagocytosis PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling G alpha (q) signalling events Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins TCR signaling Signaling by VEGF GP1b-IX-V activation signalling Downstream signal transduction Signaling by FGFR mutants Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Downstream TCR signaling Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade VEGFA-VEGFR2 Pathway Synthesis of PIPs at the plasma membrane IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events Antigen activates B Cell Receptor (BCR) leading to generation of second messengers PI Metabolism Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Interleukin receptor SHC signaling Signaling by FGFR1 fusion mutants Constitutive Signaling by EGFRvIII PI3K Cascade	E2F mediated regulation of DNA replication DNA Damage/Telomere Stress Induced Senescence Synthesis of DNA Mitotic Prophase Cellular Senescence G1 Phase Regulation of DNA replication Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes Orc1 removal from chromatin S Phase Cyclin E associated events during G1/S transition Cell Cycle, Mitotic M Phase Orc1 removal from chromatin Cyclin D associated events in G1 Formation of Senescence-Associated Heterochromatin Foci (SAHF) G1/S Transition Removal of licensing factors from origins Cyclin A:Cdk2-associated events at S phase entry Switching of origins to a post-replicative state Mitotic G1-G1/S phases Condensation of Prophase Chromosomes Inhibition of replication initiation of damaged DNA by RB1/E2F1	Isoproterenol (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
BCL2 and PSEN1	B-cell CLL/lymphoma 2	presenilin 1	Activation of BAD and translocation to mitochondria Inflammasomes The NLRP1 inflammasome Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways Programmed Cell Death Activation of BH3-only proteins BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Innate Immune System Intrinsic Pathway for Apoptosis	Degradation of the extracellular matrix	Ibuprofen Paclitaxel Docetaxel Rasagiline
BCL2 and CYCS	B-cell CLL/lymphoma 2	cytochrome c, somatic	Activation of BAD and translocation to mitochondria Inflammasomes The NLRP1 inflammasome Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways Programmed Cell Death Activation of BH3-only proteins BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Innate Immune System Intrinsic Pathway for Apoptosis	Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. Organelle biogenesis and maintenance Detoxification of Reactive Oxygen Species Respiratory electron transport Cytochrome c-mediated apoptotic response Mitochondrial biogenesis Activation of caspases through apoptosome-mediated cleavage Formation of apoptosome Release of apoptotic factors from the mitochondria Apoptotic factor-mediated response Programmed Cell Death Transcriptional activation of mitochondrial biogenesis The citric acid (TCA) cycle and respiratory electron transport Orphan transporters Intrinsic Pathway for Apoptosis	Ibuprofen Paclitaxel Docetaxel Rasagiline	Minocycline Protoporphyrin Ix Containing Co Heme Heme C Protoporphyrin Ix Containing Zn N-Trimethyllysine Zinc Substituted Heme C
BCL2 and HRK	B-cell CLL/lymphoma 2	harakiri, BCL2 interacting protein	Activation of BAD and translocation to mitochondria Inflammasomes The NLRP1 inflammasome Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways Programmed Cell Death Activation of BH3-only proteins BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members Innate Immune System Intrinsic Pathway for Apoptosis		Ibuprofen Paclitaxel Docetaxel Rasagiline
HRAS and PIK3R1	Harvey rat sarcoma viral oncogene homolog	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Signaling by FGFR in disease SHC-mediated cascade MEK activation FCERI mediated MAPK activation CREB phosphorylation through the activation of Ras Signaling by EGFRvIII in Cancer SHC1 events in ERBB2 signaling Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling Gastrin-CREB signalling pathway via PKC and MAPK p38MAPK events EPH-Ephrin signaling SOS-mediated signalling Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell SHC-mediated signalling Signaling by PDGF DAP12 interactions SHC-related events triggered by IGF1R GRB2 events in EGFR signaling Signaling by ERBB4 Signaling by ERBB2 Signaling by EGFR Signaling by Interleukins SHC1 events in ERBB4 signaling Signaling by VEGF Signalling to RAS Downstream signal transduction Signaling by FGFR mutants Signaling by EGFR in Cancer Fc epsilon receptor (FCERI) signaling Interleukin-2 signaling Interleukin-3, 5 and GM-CSF signaling Frs2-mediated activation Transmission across Chemical Synapses Ras activation uopn Ca2+ infux through NMDA receptor Adaptive Immune System Signaling by Leptin Signalling to ERKs Prolonged ERK activation events Axon guidance IRS-mediated signalling IGF1R signaling cascade VEGFA-VEGFR2 Pathway EPHB-mediated forward signaling IRS-related events triggered by IGF1R EGFR Transactivation by Gastrin VEGFR2 mediated cell proliferation GRB2 events in ERBB2 signaling Activation of NMDA receptor upon glutamate binding and postsynaptic events RAF phosphorylates MEK Downstream signaling of activated FGFR NCAM signaling for neurite out-growth RAF/MAP kinase cascade Signalling to p38 via RIT and RIN Post NMDA receptor activation events Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade SOS-mediated signalling SHC-mediated signalling IRS-related events Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer SHC-related events NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR ARMS-mediated activation SHC1 events in EGFR signaling RAF activation IRS-mediated signalling FRS2-mediated cascade Activation of RAS in B cells Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) Interleukin receptor SHC signaling Constitutive Signaling by EGFRvIII	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by FGFR1 mutants Interleukin-7 signaling Role of phospholipids in phagocytosis Phospholipid metabolism Fcgamma receptor (FCGR) dependent phagocytosis PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling G alpha (q) signalling events Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins TCR signaling Signaling by VEGF GP1b-IX-V activation signalling Downstream signal transduction Signaling by FGFR mutants Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Downstream TCR signaling Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade VEGFA-VEGFR2 Pathway Synthesis of PIPs at the plasma membrane IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events Antigen activates B Cell Receptor (BCR) leading to generation of second messengers PI Metabolism Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Interleukin receptor SHC signaling Signaling by FGFR1 fusion mutants Constitutive Signaling by EGFRvIII PI3K Cascade	Hexane-1,6-Diol Trifluoroethanol Guanosine-5\'-Triphosphate Guanosine-5\'-Diphosphate N,N\'-DIMETHYL-N-(ACETYL)-N\'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE	Isoproterenol (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
CDH1 and PSEN1	cadherin 1, type 1, E-cadherin (epithelial)	presenilin 1	Cell junction organization Apoptotic cleavage of cellular proteins Adherens junctions interactions Apoptotic execution phase Degradation of the extracellular matrix Apoptotic cleavage of cell adhesion proteins Cell-cell junction organization Programmed Cell Death Integrin cell surface interactions Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell Adaptive Immune System	Degradation of the extracellular matrix
CTNNB1 and PSEN1	catenin (cadherin-associated protein), beta 1, 88kDa	presenilin 1	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Degradation of the extracellular matrix	Urea
APP and CTNNB1	amyloid beta (A4) precursor protein	catenin (cadherin-associated protein), beta 1, 88kDa	Signaling by GPCR Platelet degranulation Metabolic disorders of biological oxidation enzymes RIP-mediated NFkB activation via ZBP1 Formyl peptide receptors bind formyl peptides and many other ligands Amyloids Toll Like Receptor TLR1:TLR2 Cascade Peptide ligand-binding receptors Toll Like Receptor 5 (TLR5) Cascade The NLRP3 inflammasome Gastrin-CREB signalling pathway via PKC and MAPK Response to elevated platelet cytosolic Ca2+ MyD88 dependent cascade initiated on endosome Toll Like Receptor 9 (TLR9) Cascade G alpha (i) signalling events TRIF-mediated TLR3/TLR4 signaling Toll Like Receptor 2 (TLR2) Cascade G alpha (q) signalling events GPCR downstream signaling Toll Like Receptor 4 (TLR4) Cascade Toll Like Receptor 3 (TLR3) Cascade Platelet activation, signaling and aggregation TAK1 activates NFkB by phosphorylation and activation of IKKs complex Defective ACTH causes Obesity and Pro-opiomelanocortinin deficiency (POMCD) G alpha (q) signalling events Class A/1 (Rhodopsin-like receptors) Toll Like Receptor 7/8 (TLR7/8) Cascade Toll Like Receptor TLR6:TLR2 Cascade DEx/H-box helicases activate type I IFN and inflammatory cytokines production Activated TLR4 signalling MyD88 cascade initiated on plasma membrane ZBP1(DAI) mediated induction of type I IFNs ECM proteoglycans MyD88:Mal cascade initiated on plasma membrane TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation Advanced glycosylation endproduct receptor signaling Innate Immune System Inflammasomes Cytosolic sensors of pathogen-associated DNA MyD88-independent cascade GPCR ligand binding Toll-Like Receptors Cascades RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways Toll Like Receptor 10 (TLR10) Cascade Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways TRAF6 mediated NF-kB activation	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer		Urea
CTNNB1 and PSEN2	catenin (cadherin-associated protein), beta 1, 88kDa	presenilin 2	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by NOTCH1 HD Domain Mutants in Cancer Axon guidance Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer Signaling by NOTCH1 t(7;9)(NOTCH1:M1580_K2555) Translocation Mutant Signaling by NOTCH2 EPH-ephrin mediated repulsion of cells Signaling by NOTCH1 EPH-Ephrin signaling Signaling by NOTCH1 in Cancer Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants FBXW7 Mutants and NOTCH1 in Cancer Signaling by NOTCH4 Regulated proteolysis of p75NTR Signalling by NGF Cell death signalling via NRAGE, NRIF and NADE Signaling by NOTCH p75 NTR receptor-mediated signalling Signaling by ERBB4 NOTCH2 Activation and Transmission of Signal to the Nucleus Activated NOTCH1 Transmits Signal to the Nucleus Nuclear signaling by ERBB4 NRIF signals cell death from the nucleus Signaling by NOTCH1 PEST Domain Mutants in Cancer Signaling by NOTCH3 Constitutive Signaling by NOTCH1 PEST Domain Mutants	Urea
BCL3 and CTNNB1	B-cell CLL/lymphoma 3	catenin (cadherin-associated protein), beta 1, 88kDa		APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer		Urea
CTNNB1 and PIK3R1	catenin (cadherin-associated protein), beta 1, 88kDa	phosphoinositide-3-kinase, regulatory subunit 1 (alpha)	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	Signaling by the B Cell Receptor (BCR) Signaling by GPCR Metabolism of lipids and lipoproteins Signaling by FGFR in disease Signaling by EGFRvIII in Cancer Signaling by SCF-KIT Downstream signaling events of B Cell Receptor (BCR) DAP12 signaling PI3K/AKT activation Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants Interleukin receptor SHC signaling PI-3K cascade Gastrin-CREB signalling pathway via PKC and MAPK Signaling by FGFR1 mutants Interleukin-7 signaling Role of phospholipids in phagocytosis Phospholipid metabolism Fcgamma receptor (FCGR) dependent phagocytosis PI3K Cascade Signaling by PDGF DAP12 interactions GAB1 signalosome G-protein beta:gamma signalling CD28 co-stimulation CD28 dependent PI3K/Akt signaling Signaling by ERBB4 Constitutive PI3K/AKT Signaling in Cancer Role of LAT2/NTAL/LAB on calcium mobilization PI3K events in ERBB4 signaling G alpha (q) signalling events Signaling by ERBB2 Signaling by EGFR GPCR downstream signaling Signaling by Interleukins TCR signaling Signaling by VEGF GP1b-IX-V activation signalling Downstream signal transduction Signaling by FGFR mutants Fc epsilon receptor (FCERI) signaling Signaling by EGFR in Cancer Nephrin interactions Interleukin-2 signaling PI3K/AKT Signaling in Cancer Platelet activation, signaling and aggregation Interleukin-3, 5 and GM-CSF signaling Adaptive Immune System G alpha (q) signalling events Downstream TCR signaling Costimulation by the CD28 family IRS-mediated signalling PIP3 activates AKT signaling IGF1R signaling cascade VEGFA-VEGFR2 Pathway Synthesis of PIPs at the plasma membrane IRS-related events triggered by IGF1R G beta:gamma signalling through PI3Kgamma PI3K events in ERBB2 signaling Regulation of signaling by CBL Downstream signaling of activated FGFR G alpha (12/13) signalling events Antigen activates B Cell Receptor (BCR) leading to generation of second messengers PI Metabolism Innate Immune System Signaling by Insulin receptor Signalling by NGF Insulin receptor signalling cascade Cytokine Signaling in Immune system Signaling by Ligand-Responsive EGFR Variants in Cancer IRS-related events NGF signalling via TRKA from the plasma membrane Tie2 Signaling Signaling by Overexpressed Wild-Type EGFR in Cancer Cell surface interactions at the vascular wall Signaling by FGFR IRS-mediated signalling Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) GPVI-mediated activation cascade Interleukin receptor SHC signaling Signaling by FGFR1 fusion mutants Constitutive Signaling by EGFRvIII PI3K Cascade	Urea	Isoproterenol (1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-[(METHYLOXY)METHYL]-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO[4,3,2-DE]INDENO[4,5-H][2]BENZOPYRAN-11-YL ACETATE
CTNNB1 and CDON	catenin (cadherin-associated protein), beta 1, 88kDa	cell adhesion associated, oncogene regulated	APC truncation mutants have impaired AXIN binding misspliced GSK3beta mutants stabilize beta-catenin T41 mutants of beta-catenin aren't phosphorylated TCF7L2 mutants don't bind CTBP truncated APC mutants destabilize the destruction complex Signaling by Wnt binding of TCF/LEF:CTNNB1 to target gene promoters deactivation of the beta-catenin transactivating complex APC truncation mutants are not K63 polyubiquitinated disassembly of the destruction complex and recruitment of AXIN to the membrane S37 mutants of beta-catenin aren't phosphorylated Degradation of beta-catenin by the destruction complex AXIN mutants destabilize the destruction complex, activating WNT signaling RNF mutants show enhanced WNT signaling and proliferation S33 mutants of beta-catenin aren't phosphorylated XAV939 inhibits tankyrase, stabilizing AXIN Innate Immune System truncations of AMER1 destabilize the destruction complex CDO in myogenesis misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling Cytosolic sensors of pathogen-associated DNA formation of the beta-catenin:TCF transactivating complex phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex AXIN missense mutants destabilize the destruction complex S45 mutants of beta-catenin aren't phosphorylated repression of WNT target genes beta-catenin independent WNT signaling deletions in the AMER1 gene destabilize the destruction complex Ca2+ pathway Myogenesis AMER1 mutants destabilize the destruction complex TCF dependent signaling in response to WNT LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling Signaling by WNT in cancer	CDO in myogenesis Myogenesis Hedgehog 'on' state Signaling by Hedgehog Ligand-receptor interactions	Urea

Search Results for: Alzheimer